• Intravesical p21 mRNA-LNP Restores Tumor Suppression in Blad

  2026-06-29

  This study demonstrates that intravesical delivery of p21 mRNA-loaded lipid nanoparticles (LNPs) effectively restores tumor suppressor function and reduces tumor growth in bladder cancer models. The findings highlight a clinically relevant, localized mRNA-based therapy with minimal systemic toxicity and significant translational promise.

• Applied Uses of the Alcian Blue & Nuclear Fast Red Staining

  2026-06-28

  The Alcian Blue & Nuclear Fast Red Staining Kit, pH2.5 excels in rapid, high-contrast mucopolysaccharide and chondrogenic differentiation staining, streamlining workflows for stem cell and tissue research. This guide unpacks experimental best practices, real-world troubleshooting, and actionable protocol enhancements for reproducible results.

• AO/PI Double Staining Kit: Practical Guide for Cell Viabilit

  2026-06-27

  The AO/PI Double Staining Kit enables rapid discrimination of viable, apoptotic, and necrotic cells using dual fluorescent dyes. This solution is ideal for researchers seeking precise cell viability, apoptosis, and necrosis detection in diverse cell biology workflows. It should not be used where non-fluorescent or non-nucleated cells predominate, or where light-sensitive workflows cannot accommodate AO/PI staining.

• Regorafenib (BAY 73-4506): Mechanisms and Benchmarks in Onco

  2026-06-26

  Regorafenib (BAY 73-4506) is a multi-kinase inhibitor with potent anti-angiogenic and anti-tumor activities, validated in melanoma and multiple solid tumor models. Its actions include inhibition of VEGFR1/2/3, PDGFRβ, and disruption of RRM2 and ERK/E2F3 signaling. This article provides structured, evidence-focused guidance for cancer biology research with Regorafenib.

• Cryoablation Modulates Tregs and TGF-β Pathway in Lung Adeno

  2026-06-26

  Lin et al. reveal that cryoablation in lung adenocarcinoma not only reduces regulatory T cell (Treg) populations but also suppresses the TGF-β signaling pathway, thereby enhancing antitumor immunity. Their integrative single-cell and bulk RNA-seq approach clarifies how immune microenvironmental remodeling via TGF-β/Smad2 inhibition underpins this therapeutic effect, offering a mechanistic basis for optimizing cryoablation-based therapies.

• VE-822: Redefining ATR Inhibition for Translational Cancer R

  2026-06-25

  Explore the advanced mechanistic landscape and translational strategies for integrating VE-822—a potent ATR inhibitor—into cutting-edge DNA damage response research. Gain actionable guidance for pancreatic ductal adenocarcinoma (PDAC) models, discover novel intersections with nuclear cGAS biology, and access protocol insights calibrated for reproducible, high-impact cancer sensitization studies.

• Naftifine HCl: Optimizing Workflows in Antifungal Research

  2026-06-25

  Naftifine HCl, a high-purity allylamine antifungal agent from APExBIO, empowers researchers to design robust, mechanism-driven assays targeting fungal sterol biosynthesis. This guide delivers actionable workflows, protocol innovations, and troubleshooting strategies to maximize reproducibility and data quality in dermatophyte research.

• MRT68921: Precision ULK1 Kinase Inhibition for Autophagy Res

  2026-06-24

  MRT68921 empowers researchers with nanomolar precision in blocking the autophagy initiation pathway through selective dual ULK1/2 kinase inhibition. This article delivers actionable workflows, troubleshooting insights, and advanced applications, contextualized by the latest paradigm-shifting findings in autophagy signaling.

• Tigecycline in Translational Research: Mechanisms and Strate

  2026-06-23

  Explore the mechanistic underpinnings and translational opportunities of Tigecycline, a pioneering glycylcycline antibiotic. This article synthesizes contemporary resistance dynamics, experimental protocols, and actionable guidance for addressing multidrug-resistant pathogens—bridging bench and bedside for next-generation infectious disease research.

• Palonosetron Hydrochloride (SKU B2229): Reliable 5-HT3 Antag

  2026-06-23

  This article offers a scenario-driven, evidence-based roadmap for biomedical researchers and lab professionals seeking reproducible 5-HT3 receptor antagonist performance in cell viability, transporter, and antiemetic modeling assays. Using 'Palonosetron hydrochloride' (SKU B2229) as a reference, we address practical challenges—from protocol optimization to vendor selection—backed by quantitative data and peer-reviewed sources.

• HBTU: Precision Peptide Bond Formation for Advanced Synthesi

  2026-06-22

  HBTU (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) is a gold-standard reagent for racemization-resistant peptide bond formation. Its unique solubility, stability, and rapid activation enable high-yield, large-scale peptide synthesis, making it essential for next-generation enzyme-responsive therapeutics.

• AG-126 (Tyrphostin AG-126): Advanced Insights for ERK Pathwa

  2026-06-22

  Discover the scientific depth of AG-126 (Tyrphostin AG-126), a selective ERK1/2 inhibitor, and its unique applications in dissecting MAPK/ERK signaling. This article offers new perspectives on assay design, translational modeling, and the neurobiological relevance of ERK pathway modulation.

• Cyclosporin A: Protocols and Best Practices for Research Use

  2026-06-21

  Cyclosporin A (cyclosporine) is a potent immunosuppressant and cyclophilin inhibitor, widely used in autoimmune disorder research, apoptosis modulation, and viral entry inhibition models. This article outlines actionable protocols, QC guidance, and key limitations for researchers using Cyclosporin A in cell and animal workflows. It is not intended for clinical or diagnostic use beyond preclinical models.

• Palonosetron Hydrochloride: Advancing 5-HT3 Antagonist Thera

  2026-06-20

  This review examines the pharmacological, pharmacokinetic, and clinical features of palonosetron hydrochloride as detailed in the reference study, emphasizing its distinctive selectivity and prolonged antiemetic activity. The findings support its superiority for both acute and delayed chemotherapy-induced and radiotherapy-induced nausea and vomiting, with implications for translational and clinical research.

• TAK-715 and the Dual-Modulation of p38α MAPK: Advanced Insig

  2026-06-19

  Explore TAK-715, a potent p38 MAPK inhibitor, through the lens of dual-action kinase modulation and structural selectivity. This article offers advanced scientific analysis and unique protocol guidance for inflammation and cytokine signaling research.

450 records 13/30 page Previous Next First page 上5页 1112131415 下5页 Last page